Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Teratogenicity01:07

Teratogenicity

2.4K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Primary ovarian malignant melanoma: A systematic review of cases and pooled analysis.

Gynecologic oncology·2026
Same author

Depth of response to primary POMB/ACE chemotherapy predicts survival in poor prognosis germ-cell tumours.

British journal of cancer·2026
Same author

Malignant Adult Ovarian Germ Cell Tumors: An International Multicenter Study to Identify Relevant Prognostic Risk Factors for Stage IC and Beyond.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Comparison of efficacy and toxicity of 2 dactinomycin (ACTD) regimens in the second-line treatment of low-risk gestational trophoblastic neoplasia: a retrospective study.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
Same author

How to design a ROCI (Response Over Continuous Intervention) randomised trial: guidance and a case study.

BMC medical research methodology·2026
Same author

Primary Uterine Nongestational Placental Site Trophoblastic Tumor as a Distinct Entity: A Report of 5 Cases.

The American journal of surgical pathology·2026

Related Experiment Video

Updated: Jun 12, 2025

In Vitro Differentiation of Human Pluripotent Stem Cells into Trophoblastic Cells
08:21

In Vitro Differentiation of Human Pluripotent Stem Cells into Trophoblastic Cells

Published on: March 16, 2017

8.6K

Future Directions for Gestational Trophoblastic Disease.

Ehsan Ghorani1, Michael J Seckl1

  • 1Department of Medical Oncology, Gestational Trophoblastic Disease Centre, Imperial College Healthcare NHS Trust, Charing Cross Hospital, London W6 8RF, UK.

Hematology/Oncology Clinics of North America
|September 25, 2024
PubMed
Summary

Gestational trophoblastic disease (GTD) management is improving with specialized care and novel therapies like immunotherapy. Expanding access to expert centers and advanced treatments is crucial for reducing mortality and treatment side effects globally.

Keywords:
Early detectionGTDGlobal healthImmunotherapyMolecular diagnostics

More Related Videos

Protocol for the Direct Conversion of Murine Embryonic Fibroblasts into Trophoblast Stem Cells
08:57

Protocol for the Direct Conversion of Murine Embryonic Fibroblasts into Trophoblast Stem Cells

Published on: July 25, 2016

7.6K
Trophoblast Cell Recovery from Angiogenesis-Tube Formation Assay for Differentiation Marker Expression Analysis
05:30

Trophoblast Cell Recovery from Angiogenesis-Tube Formation Assay for Differentiation Marker Expression Analysis

Published on: November 8, 2024

372

Related Experiment Videos

Last Updated: Jun 12, 2025

In Vitro Differentiation of Human Pluripotent Stem Cells into Trophoblastic Cells
08:21

In Vitro Differentiation of Human Pluripotent Stem Cells into Trophoblastic Cells

Published on: March 16, 2017

8.6K
Protocol for the Direct Conversion of Murine Embryonic Fibroblasts into Trophoblast Stem Cells
08:57

Protocol for the Direct Conversion of Murine Embryonic Fibroblasts into Trophoblast Stem Cells

Published on: July 25, 2016

7.6K
Trophoblast Cell Recovery from Angiogenesis-Tube Formation Assay for Differentiation Marker Expression Analysis
05:30

Trophoblast Cell Recovery from Angiogenesis-Tube Formation Assay for Differentiation Marker Expression Analysis

Published on: November 8, 2024

372

Area of Science:

  • Gynecology
  • Oncology
  • Reproductive Medicine

Background:

  • Gestational trophoblastic disease (GTD) is a group of premalignant and malignant conditions.
  • Centralized care models significantly enhance survival rates for GTD patients.
  • Many regions lack specialized GTD centers, contributing to preventable mortality.

Purpose of the Study:

  • To review current research in refining diagnostic and treatment methods for GTD.
  • To highlight the potential of immunotherapy as a less toxic alternative to chemotherapy.
  • To emphasize the need for global expansion of specialized care and integration of new therapies.

Main Methods:

  • Review of current research and treatment modalities for GTD.
  • Analysis of survival rates in relation to care models.
  • Evaluation of immunotherapy efficacy and side effect profiles.

Main Results:

  • Specialized care centers are linked to improved GTD survival.
  • Immunotherapy shows promise as a high-cure, low-side-effect treatment option.
  • Refined diagnostics and risk prediction are key research areas.

Conclusions:

  • Improving GTD outcomes requires global access to specialized care.
  • Integrating advanced therapies like immunotherapy can reduce treatment harm.
  • Continued research is vital for better risk prediction and personalized treatment strategies.